Advicenne stock | 2026 forecast, price target & growth

Advicenne

ENXTPA:ALDVI

€ 1,57

€-0,38 (-19,49%)

1,57 €

€-0,38 (-19,49%)

End-of-day quote: 03/27/2026

Advicenne Stock Value

The analyst rating for Advicenne is currently Buy.

Buy

Advicenne Company Info

EPS Growth 5Y

22,57%

Market Cap

€0,02 B

Long-Term Debt

€0,02 B

Quarterly earnings

06/18/2026 (E)

Dividend

€0,00

Dividend Yield

0,00%

Founded

2007

Industry

Health Care

Country

France

Website

Advicenne

ISIN Number

FR0013296746

Website

http://www.advicenne.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€3,50

122.93%

Last Update: 03/30/2026

Analysts: 2

Highest Price Target €4,00

Average Price Target €3,50

Lowest Price Target €3,00

In the last five quarters, Advicenne’s Price Target has fallen from €6,00 to €4,00 - a -33,33% decrease. Two analysts predict that Advicenne’s share price will increase in the coming year, reaching €3,50. This would represent an increase of 122,93%.

Top growth stocks in the health care sector (5Y.)

What does Advicenne do?

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Business Segments The company operates through several key segments, each reflecting the company’s focus on addressing unmet medical needs in specific therapeutic areas. The primary business segments include the development and commercialization of pharmaceutical products for Nephrology, Neurology, and Other Rare Diseases, with a particular emphasis on pediatric and orp...

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases.

Business Segments

The company operates through several key segments, each reflecting the company’s focus on addressing unmet medical needs in specific therapeutic areas. The primary business segments include the development and commercialization of pharmaceutical products for Nephrology, Neurology, and Other Rare Diseases, with a particular emphasis on pediatric and orphan drug markets.

The Nephrology segment is centered on the development of treatments for rare kidney disorders, such as distal renal tubular acidosis (dRTA). The company’s lead product, Sibnayal (ADV7103), is a proprietary formulation designed to address the limitations of existing therapies for dRTA. This segment involves extensive research and clinical development activities, including the design and execution of clinical trials, regulatory submissions, and post-marketing surveillance.

The Neurology segment focuses on the development of therapies for rare and severe neurological disorders. This segment involves close collaboration with academic institutions and clinical research centers to advance the understanding of disease mechanisms and to develop targeted interventions.

In addition to nephrology and neurology, the company is engaged in the development of products for Other Rare Diseases, leveraging its capabilities in formulation science and regulatory affairs.

Business Strategy

The company’s business strategy is centered on the identification, development, and commercialization of innovative pharmaceutical products that address significant unmet medical needs, particularly in the fields of nephrology and neurology.

The company’s strategy involves a targeted approach to product development, focusing on diseases with high unmet needs and limited treatment options. The company seeks to develop proprietary formulations of existing molecules, optimizing their efficacy, safety, and patient compliance. The company’s flagship product, Sibnayal (ADV7103), exemplifies this approach, offering a novel treatment option for patients with distal renal tubular acidosis.

Products and Services

The company’s product portfolio is focused on the development and commercialization of innovative pharmaceutical products for rare and severe diseases, with a particular emphasis on pediatric and orphan drug markets. The company’s flagship product, Sibnayal (ADV7103), is a proprietary formulation developed for the treatment of distal renal tubular acidosis (dRTA), a rare kidney disorder.

In addition to Sibnayal, the company is engaged in the development of other drug candidates targeting rare diseases in nephrology and neurology. The company’s pipeline includes products at various stages of development, from preclinical research to clinical trials and regulatory approval.

Geographical Markets

The company operates primarily in France and the European Union, with a focus on the development and commercialization of pharmaceutical products for rare and severe diseases.

Dispositions

As of the date of the Universal Registration Document, the company no longer holds any subsidiaries. The wholly-owned subsidiary Advicenne Inc. was dissolved on December 7, 2023.

Customers

The company’s primary customers are likely to include healthcare professionals, hospitals, clinics, and pharmacies involved in the treatment of rare and severe diseases, particularly in the fields of nephrology and neurology. The company’s marketing and distribution activities are designed to reach these customer segments through direct sales, partnerships, and collaborations with distributors and wholesalers.

Trade Names

The company’s flagship product, Sibnayal (ADV7103), is protected by patents and regulatory exclusivities.

Sales and Marketing

The company employs a multi-channel distribution strategy for the commercialization of its products. The company’s sales and marketing activities include direct sales to healthcare professionals and institutions, partnerships with pharmaceutical companies, and collaborations with distributors and wholesalers. The company’s marketing efforts are focused on raising awareness of its products among healthcare professionals, patients, and payers, with an emphasis on demonstrating the clinical and economic value of its therapies.

History

Advicenne S.A. was founded in 2007. The company was incorporated in 2007.

New support ticket

Explore

Advicenne Stock Value

Advicenne Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Advicenne do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Advicenne Stock Value

Advicenne Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Advicenne do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.